Work

Abstract CT146: Safety, tolerability and molecular correlates of the IRF4-targeted antisense oligonucleotide frenlosirsen in patients with relapsed/refractory multiple myeloma: A phase 1a dose escalation trial

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-ct146

Authors: Alexander A. Tong, Silvia Vicenzi, Lara C. Avsharian, Joshua D. Hartman, Trung V. Tran, Ashni A. Vora, Robert A. Vescio, Barry A. Paul, Caitlin L. Costello, T. Jesse Kwoh, Leslie A. Crews

Institutions: University of California San Diego, Moores Cancer Center, Cedars-Sinai Medical Center, Levine Cancer Institute, Ionis Pharmaceuticals (United States)

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409821966

Cites:

Cited by: 2

Related to: 10